Moteur de recherche d’entreprises européennes
Financement de l’UE (12 M €) : Autonomisation de la recherche sur les transporteurs de solutés (ReSOLUTE) Hor 01/07/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Autonomisation de la recherche sur les transporteurs de solutés (ReSOLUTE)
The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in the intensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is composed of a core consortium of seven academic/SME members (CeMM, Univ. of Oxford, Univ. of Manchester, AXXAM Spa, Univ. Leiden, Max-Planck Institut für medizinische Forschung, Univ. Wien) and six industrial partners (Pfizer Limited UK, Novartis Pharma AG, Boehringer-Ingelheim, Vifor Pharma Group, Sanofi Aventis Recherche et Développement, Bayer AG) with established and complementary expertise combining industry grade standards and systems level principle-driven analysis. ReSOLUTE merges systematic and focused approaches: 1) the generation of reliable and validated ‘hardware’ such as cell lines, proteins, antibodies/high affinity binders and large ‘omics’ datasets, 2) a central deorphanisation process coupling genomic engineering to metabolomics and supported by genetic and proteomics studies, 3) a non-redundant process to test systematically the suitability of a certain SLC to a variety of assay formats, 4) a collection of interlinked networks that cover different expertise, datasets and functional connections among SLCs, integrated into large-scale data repositories and a dedicated knowledgebase. The ReSOLUTE strategy will be applied in parallel at the super-family level and, in a more in-depth manner, to a prioritized gene list elected to be potential drug targets. To implement this and achieve the expected goals, the consortium is supported by a large network of academic and industrial partners with specific knowledge of certain SLCs and tools, willing to be accessed at any time and provide specific expertise. Together with a strong dissemination and exploitation plan, we therefore expect that ReSOLUTE will transform the landscape of SLC research for years to come.
| Axxam S.p.A. | 1 166 250 € |
| Bayer AG | 0,00 € |
| Boehringer Ingelheim Internationalgesellschaft mbH | 0,00 € |
| Cemm - Forschungszentrum Fuer Molekulare Medizin GmbH | 6 732 261 € |
| MAX-Planck-Gesellschaft ZUR Forderung DER Wissenschaften e. V. | 483 750 € |
| Novartis Pharma AG | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 1 208 850 € |
| The University of Liverpool | 1 220 267 € |
| The University of Manchester | 1 470,68 € |
| Universitat Wien | 379 813 € |
| Universiteit Leiden | 807 339 € |
| Vifor (International) AG | 0,00 € |
https://cordis.europa.eu/project/id/777372
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.